Gujarat Themis Biosyn to raise equity for ¥21.5 bn Japan deal
The board will meet June 6 to decide on a QIP, preferential allotment, or other equity route. The raise will fund last month's ¥21.5 bn acquisition of MicroBiopharm Japan.
— 2 earlier stories on Gujarat Themis Biosyn Ltd. →What's new
- Board will meet on June 6 to approve a fundraise via QIP, preferential allotment, or other equity-linked instruments.
- The move follows last month's agreement to buy Japanese CDMO MicroBiopharm Japan for ¥21.5 billion.
- The company has not disclosed the size, structure, or terms of the planned issue.
Why this matters
A small-cap Indian biotech agreed to a ¥21.5 bn acquisition it cannot fund from cash flow. The equity raise is the expected next step to close the deal, but the terms and resulting dilution for existing shareholders are still unknown.
What we're watching
- The issue size, pricing, and structure to emerge from the June 6 board meeting.
- Whether the raise is sized to cover the full acquisition cost or just a portion.
- Promoter participation and the post-allotment stake dilution.
The full read
Gujarat Themis Biosyn is calling a board meeting on June 6 to approve a fundraise. The options are a QIP, a preferential allotment, or other equity instruments. The context is clear: last month the company agreed to buy Japanese CDMO MicroBiopharm Japan for ¥21.5 billion. A small-cap Indian biotech cannot fund that from its own cash flow. The filing confirms the capital need but reveals nothing about the amount or terms. The critical unknown for existing shareholders is dilution. That question should be answered at the meeting.
Questions answered
- Why is Gujarat Themis Biosyn raising capital?
- The raise is to fund the ¥21.5 billion acquisition of Japanese CDMO MicroBiopharm Japan, which the company agreed to buy last month.
- What are the possible fundraise structures?
- The board is evaluating a qualified institutional placement, a preferential allotment, or other equity-linked instruments.
- How large will the fundraise be?
- The filing does not specify a size. The board is evaluating proposals at the June 6 meeting.
- What is the MicroBiopharm Japan deal?
- Gujarat Themis agreed last month to acquire the Japanese contract development and manufacturing organization for ¥21.5 billion.
Story so far
All notes on GUJTHEM →- 3 Jun 2026 · 6:14 PM IST Gujarat Themis Biosyn to raise equity for ¥21.5 bn Japan deal
- 9d ago Gujarat Themis Biosyn plans a cash raise. It hasn't named the price or the buyer.
- 12d ago Gujarat Themis Biosyn bets ₹1,300 cr to buy Japan's MicroBiopharm